

[Xylometazoline](#)

Essential medicine status

Section:

[28. Ear, nose and throat medicines \[c\]](#)

ATC codes: [R01AA07](#)

EMLc

Indication

Nasal congestion ICD11 code: [MF11.7](#)

INN

Xylometazoline

Medicine type

Chemical agent

List type

Core

Formulations

Local > Nasal > Spray: 0.05% equivalent to 0.5 mg per mL (EMLc)

Local > Nasal > Drops: 0.05% equivalent to 0.5 mg per mL (EMLc)

EML status history

First added in 2009 ([TRS 958](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Children (1 month - 12 years)

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations for EMLc

Therapeutic alternatives to be reviewed

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Xylometazoline](#)

DrugBank

[Xylometazoline](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of xylometazoline nasal drops 0.05%; - removal of the note regarding use in children less than 3 months.